Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Subscribe To Our Newsletter & Stay Updated